Steve1978
4 years ago
Copied from another board
We had such an incredible afternoon today at MedMira Inc. Laboratory in #ClaytonParkWest!
#MedMira has come out with a patent for #COVID19 that can detect if you have antibodies within minutes, and will show the results for days to follow (which is something that is not common with these types of tests).
Just a few short months ago, 6 months to be exact, MedMira only had 11 staff members. Today, the company has expanded to 54 people! It was truly amazing to see all of their employees who come from over 18 countries; there are 6 summer students and over 30 new immigrants.
The expansion of staff is due to the high demand for their REVEALCOVID-19 TM Total Antibody test.
One of the most valuable things we noticed is that these individuals are extremely hard-working. This job is an exceptional way for them to get the Canadian working experience and to have flourishing and enriching careers!
We felt a true sense of family and community β this is the real beauty of Canada; There is opportunity and space for everyone to work in harmony.
The staff at MedMira contribute a weekly production of over 20,000 COVID-19 tests. We are told that the external performance evaluation of this product in the United States has been exceptional.
They also plan to expand to other markets, such as Europe and Asia.
Please stay tuned for a special feature from my office, highlighting a behind-the-scenes look at MedMira Inc.
Thank you to Hermes Chan (CEO) and Markus Meile (CFO), for your information breakdown of the antibody test. As well as all the exciting things your company is doing and plans to do in the future.
We wish you the best of luck!
Paraceratherium
4 years ago
Think it is overdue, but I read that they are extra vigilant due to their past acceptance of less than adequate tests in the initial panic. Hermes Chan just posted on linked in (from stockhouse post):
The study reveals key finding about specific IgM, IgG1, and IgA1 antibody not only present in plasma or serum of almost all analyzed COVID-19 convalescent study subjects, most significantly is that these antibodies were also detected at exceptionally early stages of the infection (i.e., 7-8 days after disease onset).
This may set a new criteria and create great opportunity for serological tests used in screening convalescent plasma for the emergency therapeutic application critical for treating severe COVID-19 patients.